Imunon Inc (NASDAQ:IMNN) announced positive results from their phase 2 Ovation 2 study, showing significant improvement in ...

Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN ...

Stacy Lindborg; Independent Director; Imunon Inc. Presentation. Operator. Good morning. My name is Mike, and I will be your operator today. At this time, I would lik ...

Ended 2024 with $5.9M in cash and cash equivalents. The company believes it has sufficient capital resources to fund its operations into late ...

IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase ...

Donald P. Braun, a director at Imunon, Inc. (NASDAQ:IMNN), recently purchased 25,000 shares of the company's common stock, according to a filing with the Securities and Exchange Commission.

LAWRENCEVILLE, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company entering a pivotal Phase 3 trial of its DNA-mediated immunotherapy, today announced new ...

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also ...

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to 4-fold increase in neutralizing ...

New Jersey, USA-based Imunon announced new translational data from the Phase II OVATION 2 Study of IMNN-001, an ...

Q4 2024 Results Conference Call February 26, 2025 11:00 AM ETCompany ParticipantsPeter Vozzo - ICR Healthcare, IRStacy Lindborg ...